Shanghai Pharmaceuticals Holding Co Ltd

Chart & Performance

D1W1MN

P/E

9.43

P/S

0.14

EPS

1.29

Div Yield, %

10.53%

Shrs. gr., 5y

5.49%

Rev. gr., 5y

10.35%

Revenues

260.30b

+12.21%

Net income

3.77b

-32.92%

CFO

5.23b

+10.29%

Dividend

Sep 17, 20240.087355 HKD/sh

Earnings

Mar 26, 2025

Profile

Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People's Republic of China. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including oncology, cerebrocardiovascular, CNS, general infection, immunology, digestive and metabolism, and respiratory. It provides approximately 700 varieties of drugs. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores; online drug business; and provision of consulting services, assets management operations, as well as clinical trials, medical aid, physicians and patients' education, e-prescription management, and remote and cloud hospitals. Further, the company manufactures and trades in medicines. It operates approximately 2,000 retail chain pharmacies in 24 provinces. The company was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.

URL

https://www.sphchina.com/index/

IPO date

Mar 24, 1994

Employees

47,811

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	260,295,089 12.21%	231,981,300 7.49%	215,824,259 12.46%
Cost of revenue	242,070,319	219,082,765	203,995,917
Unusual Expense (Income)
NOPBT	18,224,770	12,898,534	11,828,342
NOPBT Margin	7.00%	5.56%	5.48%
Operating Taxes	1,887,726	1,816,339	1,869,245
Tax Rate	10.36%	14.08%	15.80%
NOPAT	16,337,043	11,082,196	9,959,097
Net income	3,768,000 -32.92%	5,617,152 10.28%	5,093,467 13.28%
Dividends	(3,981,205)	(1,552,494)	(1,364,203)
Dividend yield	6.43%	2.50%	2.42%
Proceeds from repurchase of equity
BB yield
Debt
Debt current	35,560,500	31,000,022	23,096,617
Long-term debt	8,886,308	8,863,022	10,026,300
Deferred revenue	633,481	534,581	2,349,080
Other long-term liabilities	922,510	296,175	605,101
Net debt	(7,368,365)	984,476	(1,045,790)
Cash flow
Cash from operating activities	5,231,520	4,743,361	5,061,326
CAPEX	(2,970,610)
Cash from investing activities	(2,491,873)
Cash from financing activities	231,851	12,138,594	1,565,628
FCF	11,288,093	2,857,009	9,653,573
Balance
Cash	40,669,861	37,014,951	22,390,386
Long term investments	11,145,311	1,863,617	11,778,321
Excess cash	38,800,418	27,279,502	23,377,493
Stockholders' equity	49,327,584	48,670,763	42,712,470
Invested Capital	85,344,916	88,674,314	68,638,880
ROIC	18.78%	14.09%	14.77%
ROCE	14.56%	11.02%	12.72%
EV
Common stock shares outstanding	3,701,294	3,482,740	2,842,089
Price	16.73 -6.17%	17.83 -10.27%	19.87 3.49%
Market cap	61,922,656 -0.28%	62,097,251 9.96%	56,472,315 3.49%
EV	66,356,241	74,021,172	65,133,255
EBITDA	20,411,901	15,120,975	13,968,146
EV/EBITDA	3.25	4.90	4.66
Interest	1,663,555	1,689,279	1,518,228
Interest/NOPBT	9.13%	13.10%	12.84%